vs
Apellis Pharmaceuticals, Inc.（APLS）与COMPASS MINERALS INTERNATIONAL INC（CMP）财务数据对比。点击上方公司名可切换其他公司
COMPASS MINERALS INTERNATIONAL INC的季度营收约是Apellis Pharmaceuticals, Inc.的2.0倍（$396.1M vs $199.9M），COMPASS MINERALS INTERNATIONAL INC净利率更高（4.7% vs -29.5%，领先34.2%），COMPASS MINERALS INTERNATIONAL INC同比增速更快（28.9% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-59.8M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 4.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
APLS vs CMP — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $396.1M |
| 净利润 | $-59.0M | $18.6M |
| 毛利率 | — | 16.0% |
| 营业利润率 | -25.6% | 9.2% |
| 净利率 | -29.5% | 4.7% |
| 营收同比 | -5.9% | 28.9% |
| 净利润同比 | -62.2% | 178.8% |
| 每股收益（稀释后） | $-0.40 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $396.1M | ||
| Q3 25 | $458.6M | $227.5M | ||
| Q2 25 | $178.5M | $214.6M | ||
| Q1 25 | $166.8M | $494.6M | ||
| Q4 24 | $212.5M | $307.2M | ||
| Q3 24 | $196.8M | $208.8M | ||
| Q2 24 | $199.7M | $202.9M | ||
| Q1 24 | $172.3M | $364.0M |
| Q4 25 | $-59.0M | $18.6M | ||
| Q3 25 | $215.7M | $-7.2M | ||
| Q2 25 | $-42.2M | $-17.0M | ||
| Q1 25 | $-92.2M | $-32.0M | ||
| Q4 24 | $-36.4M | $-23.6M | ||
| Q3 24 | $-57.4M | $-48.3M | ||
| Q2 24 | $-37.7M | $-43.6M | ||
| Q1 24 | $-66.4M | $-38.9M |
| Q4 25 | — | 16.0% | ||
| Q3 25 | — | 16.9% | ||
| Q2 25 | — | 19.2% | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 9.3% | ||
| Q2 24 | — | 16.1% | ||
| Q1 24 | — | 19.7% |
| Q4 25 | -25.6% | 9.2% | ||
| Q3 25 | 48.7% | 5.3% | ||
| Q2 25 | -18.6% | 7.4% | ||
| Q1 25 | -50.0% | -0.6% | ||
| Q4 24 | -12.3% | 0.2% | ||
| Q3 24 | -24.0% | -14.3% | ||
| Q2 24 | -14.7% | 2.9% | ||
| Q1 24 | -36.0% | -10.8% |
| Q4 25 | -29.5% | 4.7% | ||
| Q3 25 | 47.0% | -3.2% | ||
| Q2 25 | -23.6% | -7.9% | ||
| Q1 25 | -55.3% | -6.5% | ||
| Q4 24 | -17.1% | -7.7% | ||
| Q3 24 | -29.2% | -23.1% | ||
| Q2 24 | -18.9% | -21.5% | ||
| Q1 24 | -38.5% | -10.7% |
| Q4 25 | $-0.40 | $0.43 | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | $-0.41 | ||
| Q1 25 | $-0.74 | $-0.77 | ||
| Q4 24 | $-0.30 | $-0.57 | ||
| Q3 24 | $-0.46 | $-1.17 | ||
| Q2 24 | $-0.30 | $-1.05 | ||
| Q1 24 | $-0.54 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $46.7M |
| 总债务越低越好 | — | $890.0M |
| 股东权益账面价值 | $370.1M | $260.5M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 3.42× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $46.7M | ||
| Q3 25 | $479.2M | $59.7M | ||
| Q2 25 | $370.0M | $79.4M | ||
| Q1 25 | $358.4M | $49.5M | ||
| Q4 24 | $411.3M | $45.8M | ||
| Q3 24 | $396.9M | $20.2M | ||
| Q2 24 | $360.1M | $12.8M | ||
| Q1 24 | $325.9M | $38.3M |
| Q4 25 | — | $890.0M | ||
| Q3 25 | — | $839.8M | ||
| Q2 25 | — | $833.4M | ||
| Q1 25 | — | $807.6M | ||
| Q4 24 | — | $974.4M | ||
| Q3 24 | — | $921.2M | ||
| Q2 24 | — | $875.1M | ||
| Q1 24 | $93.1M | $877.2M |
| Q4 25 | $370.1M | $260.5M | ||
| Q3 25 | $401.2M | $234.1M | ||
| Q2 25 | $156.3M | $249.8M | ||
| Q1 25 | $164.2M | $236.5M | ||
| Q4 24 | $228.5M | $263.0M | ||
| Q3 24 | $237.1M | $316.6M | ||
| Q2 24 | $264.3M | $352.1M | ||
| Q1 24 | $266.7M | $400.4M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $821.4M | $1.5B | ||
| Q1 25 | $807.3M | $1.5B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.6B | ||
| Q2 24 | $904.5M | $1.6B | ||
| Q1 24 | $831.9M | $1.7B |
| Q4 25 | — | 3.42× | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | — | 3.34× | ||
| Q1 25 | — | 3.41× | ||
| Q4 24 | — | 3.70× | ||
| Q3 24 | — | 2.91× | ||
| Q2 24 | — | 2.49× | ||
| Q1 24 | 0.35× | 2.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-37.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-59.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -15.1% |
| 资本支出强度资本支出/营收 | 0.1% | 5.8% |
| 现金转化率经营现金流/净利润 | — | -1.99× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $94.1M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-37.0M | ||
| Q3 25 | $108.5M | $-6.9M | ||
| Q2 25 | $4.4M | $21.8M | ||
| Q1 25 | $-53.4M | $186.9M | ||
| Q4 24 | $19.4M | $-4.1M | ||
| Q3 24 | $34.1M | $-12.7M | ||
| Q2 24 | $-8.3M | $-6.8M | ||
| Q1 24 | $-133.0M | $86.2M |
| Q4 25 | $-14.3M | $-59.8M | ||
| Q3 25 | $108.3M | $-22.8M | ||
| Q2 25 | $4.4M | $3.8M | ||
| Q1 25 | $-53.4M | $172.9M | ||
| Q4 24 | $19.3M | $-25.9M | ||
| Q3 24 | — | $-33.6M | ||
| Q2 24 | $-8.4M | $-21.5M | ||
| Q1 24 | $-133.3M | $56.2M |
| Q4 25 | -7.1% | -15.1% | ||
| Q3 25 | 23.6% | -10.0% | ||
| Q2 25 | 2.5% | 1.8% | ||
| Q1 25 | -32.0% | 35.0% | ||
| Q4 24 | 9.1% | -8.4% | ||
| Q3 24 | — | -16.1% | ||
| Q2 24 | -4.2% | -10.6% | ||
| Q1 24 | -77.3% | 15.4% |
| Q4 25 | 0.1% | 5.8% | ||
| Q3 25 | 0.0% | 7.0% | ||
| Q2 25 | 0.0% | 8.4% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 7.1% | ||
| Q3 24 | 0.0% | 10.0% | ||
| Q2 24 | 0.0% | 7.2% | ||
| Q1 24 | 0.2% | 8.2% |
| Q4 25 | — | -1.99× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
